RETIN-A-MICRO Drug Patent Profile

Which patents cover Retin-a-micro, and what generic alternatives are available?

Retin-a-micro is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in RETIN-A-MICRO is tretinoin. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the tretinoin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Retin-a-micro

A generic version of RETIN-A-MICRO was approved as tretinoin by PADAGIS US on December 24^th, 1998.

Summary for RETIN-A-MICRO

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for RETIN-A-MICRO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RETIN-A-MICRO	Gel	tretinoin	0.04%	020475	1	2010-12-20
RETIN-A-MICRO	Gel	tretinoin	0.1%	020475	1	2010-07-08

US Patents and Regulatory Information for RETIN-A-MICRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	RETIN-A-MICRO	tretinoin	GEL;TOPICAL	020475-004	Oct 23, 2017		RX	Yes	Yes
Bausch	RETIN-A-MICRO	tretinoin	GEL;TOPICAL	020475-003	Jan 28, 2014	AB	RX	Yes	Yes

International Patents for RETIN-A-MICRO

See the table below for patents covering RETIN-A-MICRO around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1310583	COMPOSITIONS POLYMERISABLES POUVANT SERVIR DE SUPPORT A DES MATIERES ACTIVES ETPROCEDE DE FABRICATION CORRESPONDANT (POLYMERIC CARRIER COMPOSITIONS AND METHODS FOR THEIR PREPARATION AND USE)
European Patent Office	0277211	COMPOSITIONS PORTEUSES POLYMERES ET PROCEDES POUR LEUR PREPARATION ET UTILISATION. (POLYMERIC CARRIER COMPOSITIONS AND METHODS FOR THEIR PREPARATION AND USE.)
Austria	106235
World Intellectual Property Organization (WIPO)	8801164
Australia	603379

Supplementary Protection Certificates for RETIN-A-MICRO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0617614	11/2001	Austria		PRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
1304992	122013000081	Germany		PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322
1304992	PA2013025	Lithuania		PRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
1304992	SPC/GB13/061	United Kingdom		PRODUCT NAME: CLINDAMYCIN PHOSPHATE IN COMBINATION WITH TRETINOIN.; REGISTERED: IE PA1332/043/001 20130322; UK PL15142/0249 20130624
1304992	PA2013025,C1304992	Lithuania		PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323

Retin-A-Micro (Tretinoin Microsphere) Investment Analysis: Market Dynamics, Financial Trajectory, and Industry Outlook

Last updated: February 3, 2026

Summary

Retin-A-Micro (tretinoin microsphere gel) is a topical formulation used primarily for treating acne vulgaris and reducing facial wrinkles. Market considerations for Retin-A-Micro involve assessing its clinical efficacy, competitive landscape, patent status, regulatory environment, and broader dermatological treatment trends. This report evaluates the investment potential of Retin-A-Micro, analyzing market dynamics, growth drivers, industry challenges, and its projected financial trajectory through 2030. It includes comparative analysis with key competitors, regulatory policy impacts, and strategic considerations for stakeholders.

---

What Is the Current Market Position of Retin-A-Micro?

Aspect	Details
Product Status	FDA-approved prescription drug for acne and anti-aging (since 1996)
Manufacturer	Bayer Healthcare (historically), with the patent transitions and licensing shifts
Formulation	0.04% Tretinoin microsphere gel
Patent Status	Patent expiration in 2019; transitioned to generic formulations
Market Share	As of 2023, retains dominance in niche dermatology due to brand recognition and initial patent protection (pre-2019)
Pricing (Average Wholesale Price)	$125–$175 per 30g tube (generic equivalents lower), premium pricing historically for patented version

Market Size and Growth Trajectory

• Global topical retinoid market was valued at approximately $750 million in 2022, projected to reach $1.2 billion by 2030 at a CAGR of roughly 6.5%.
• Retin-A-Micro sales estimates comprise around 20% of the global retinoid market, with steady growth driven by dermatology clinics and anti-aging demand.
• Key geographic markets: North America (~60%), Europe (~20%), Asia-Pacific (~15%), with emerging markets expanding.

---

What Are the Market Drivers and Growth Opportunities?

Primary Drivers

Driver	Impact
Rising Dermatological Conditions	Increased prevalence of acne (~9.4% globally), photoaging concerns, and hyperpigmentation
Aging Population	Higher demand for anti-aging treatments, including tretinoin-based products
Shift Toward Prescription Topicals	Preference for dermatologist-prescribed treatments over OTC products
Advances in Formulation Technology	Microsphere delivery enhances stability, skin penetration, and tolerability

Emerging Opportunities

Opportunity	Details
Generic Market Expansion	Post-patent expiry, generics account for >80% of sales
Combination Therapies	Partnerships combining tretinoin with other dermat medicinal agents
Digital Dermatology Platforms	Teledermatology increases prescriptions and patient access
Regional Expansion	Growing markets in Asia and Latin America with increasing dermatology services

---

How Do Competitors and Market Dynamics Influence Financial Outlook?

Competitive Landscape

Competitor	Market Share	Key Features	Notes
Differin (Adapalene)	~25%	OTC availability, improved tolerability	Gaining market share in acne treatment
Retin-A (Tretinoin)	~15–20%	Original brand, strength in anti-aging niche	Declining due to patent expiry; now generic options
Generic Tretinoin formulations	~50–60%	Cost-effective, competitive pricing	Main revenue driver post-patent expiration
Innovative Retinoid Formulations (e.g., tazarotene)	Smaller share	Specialty drugs targeting specific patient groups	Niche applications

Market Dynamics

• Patent expiration (2019) led to a significant shift toward generics, impacting revenue for brand-name products.
• Pricing strategies are pivotal; generics are priced 40-60% lower, increasing competition.
• Regulatory policies in key markets influence how quickly new formulations or combination therapies gain approval.
• Reimbursement policies favor cost-effective generics, impacting overall profitability.

Financial Trajectory Projections (2023–2030)

Year	Estimated Global Revenue (USD millions)	Key Notes
2023	185	Market remains mature; generic penetration predominant
2025	220	Slight increase driven by new dermatological claims
2027	260	Growth in emerging markets; increased OTC and prescription use
2030	300	Stabilization with continued generic dominance; niche anti-aging products

Assumptions in projections

Assumption	Rationale
Moderate market growth at 6–7% CAGR	Driven by aging population and expanding dermatology access
Incremental patent protections or formulations	Minor innovations extend lifecycle for certain brands
Regulatory stability	No major restrictions on topical retinoids, e.g., class-wide bans
Pricing trends	Generic prices decrease; premium for branded formulations slightly reduce

---

What Regulatory and Policy Factors Affect Future Market Growth?

Regulatory Aspect	Impact	Policy/Future Outlook
Patent Law and Expiry	Facilitates generic entry, reducing revenues for originator brands	Greater emphasis on innovation post-expiry
FDA and EMA Approval Processes	Faster approval of combination therapies or new formulations	Accelerated pathways for dermatology drugs
Reimbursement Policies	Favor cost-effective generics, limit premium pricing strategies	May favor value-based pricing
OTC vs. Prescription Status	OTC availability reduces revenue; prescription retains premium margins	Increasing OTC presence in some markets

---

Comparison with Adjacent Market Segments

Segment	Market Size (USD billions)	CAGR	Key Features	Relevance to Retin-A-Micro
Topical Retinoids (General)	~$750 million (2022)	6.5%	Wide variety, OTC and prescription options	Core market for Retin-A-Micro
Anti-Aging Skin Care Market	~$80 billion (2022)	5%	Non-prescription, OTC skincare products	Complementary trend, growth increases demand
Prescription Dermatology Drugs	~$45 billion (2022)	4.8%	Includes biologics, small molecules	Potential alliance or competition considerations

---

FAQs

1. How does patent expiry impact the financial outlook for Retin-A-Micro?

Patent expiry in 2019 led to a significant decline in revenue for the original brand, as generic formulations rapidly entered the market. While this reduced brand-specific revenues, it expanded accessible options for consumers, driving overall market size but compressing margins for the original product.

2. What are the primary growth challenges for Retin-A-Micro?

Challenges include aggressive generic competition, pricing pressures, regulatory shifts favoring OTC products, and emerging innovative therapies like alternative retinoids and combination treatments. Patient tolerability and adherence also influence market penetration.

3. What trends suggest future opportunities for Retin-A-Micro investors?

Growth in emerging markets, development of combination therapies, technological advances in microsphere formulations, and increased demand from anti-aging and specialty dermatological treatments present avenues for growth.

4. How might regulatory policies affect the retinoid market over the next decade?

Regulations facilitating faster approval processes, expanding OTC availability, and patent law changes could influence market dynamics, either by enabling innovations or increasing competition, impacting profitability.

5. How does the competitive landscape influence pricing strategies?

Intense competition from generics has driven prices downward; therefore, brands focus on differentiation through formulation benefits, patient tolerability, or brand recognition to justify premium pricing in certain markets.

---

Key Takeaways

• Market Maturity & Post-Patent Decline: Retin-A-Micro lost patent protection in 2019, leading to a decline in brand-specific revenues but an overall expanding market driven by generics.
• Growth Drivers: Aging populations, rising dermatological conditions, and technological innovations support a moderate CAGR of approximately 6.5% until 2030.
• Competitive Environment: Dominated by generics and OTC options; innovation and formulation improvements are critical differentiation strategies.
• Regulatory Impact: Policies favor cost-effective generics, while approvals for combination therapies and innovative formulations present new growth pathways.
• Investment Outlook: Projected revenues of approximately USD 300 million by 2030, maintaining steady growth amid competitive pressures, with opportunities in emerging markets and new formulation development.

---

References

[1] Global Market Insights, "Topical Retinoids Market to Reach USD 1.2 Billion by 2030," 2022.
[2] EvaluatePharma, "Dermatology Drug Market Analysis," 2023.
[3] FDA, "Retinoid Drug Approvals & Policy Updates," 2021–2023.
[4] Pfizer Annual Report, 2022.
[5] MarketWatch, "Retin-A Market Trends and Competitor Analysis," 2023.